{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "G",
          "alt": "D",
          "position": "309"
        },
        "variant_string_id": "PINK1 G309D"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the mitochondrial PTEN-induced kinase1 (PINK1) are important causes of recessive Parkinson disease (PD). Studies on loss of function and overexpression implicate PINK1 in apoptosis, abnormal mitochondrial morphology, impaired dopamine release and motor deficits.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to mitochondrial dysfunction, apoptosis, and impaired dopamine release, all of which are relevant to Parkinson's disease pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "PINK1 clinical mutations also show reduced Complex I function and concomitant defects in synaptic function.",
          "judgment": "Yes",
          "reasoning": "The general class of assay, assessing Complex I function, is applicable because mitochondrial dysfunction is implicated in the disease mechanism of Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Pink1+/+ and Pink1-/- mouse liver and brain",
          "judgment": "Yes",
          "reasoning": "The study used both wild-type (Pink1+/+) and knockout (Pink1-/-) controls. The text implies replicates were used (mitochondrial oxygen consumption assays were performed in the presence of 5 mM glutamate/2.5 mM malate for the analysis of Complex I-driven respiration...Data represent the average ± SEM of three independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Pink1-/- cells were rescued with human wild-type or with PINK1-containing clinical mutations. Human PINK1 (hPinklres) fully complemented Complex I enzymatic activity in Pink1¯/¯ mouse fibroblasts (Fig 5B and 6B). In contrast, two PD PINK1 clinical mutations G309D (Gly309 → Asp)",
          "judgment": "Yes",
          "reasoning": "The study tested a known pathogenic variant (G309D) and used wild-type PINK1 as a control, fitting the criteria of using variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was done using the unpaired Student's t-test, where ***p = 0.00006, where **p < 0.004 and *p < 0.01 (Graph Pad Prism5 software).",
          "judgment": "No",
          "reasoning": "The study uses statistical tests (t-test) and provides p-values, but does not calculate or provide sufficient information to calculate OddsPath. ",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "NA",
          "judgment": "Yes",
          "reasoning": "Variant control testing was done using  PINK1 clinical mutations G309D. The study also rescued  PINK1−/− cells with wild-type human PINK1 (hPINK1res)",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "PINK1 G309D has supporting pathogenic functional evidence. Assays on Complex I function are considered to be applicable. Basic controls were used and there were known pathogenic variants used as controls. However, OddsPath could not be calculated and the number of pathogenic variants was fewer than 11."
    },
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "W",
          "alt": "X",
          "position": "437"
        },
        "variant_string_id": "PINK1 W437X"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations of the mitochondrial PTEN-induced kinase1 (PINK1) are important causes of recessive Parkinson disease (PD). Studies on loss of function and overexpression implicate PINK1 in apoptosis, abnormal mitochondrial morphology, impaired dopamine release and motor deficits.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to mitochondrial dysfunction, apoptosis, and impaired dopamine release, all of which are relevant to Parkinson's disease pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "PINK1 clinical mutations also show reduced Complex I function and concomitant defects in synaptic function.",
          "judgment": "Yes",
          "reasoning": "The general class of assay, assessing Complex I function, is applicable because mitochondrial dysfunction is implicated in the disease mechanism of Parkinson's disease.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Pink1+/+ and Pink1-/- mouse liver and brain",
          "judgment": "Yes",
          "reasoning": "The study used both wild-type (Pink1+/+) and knockout (Pink1-/-) controls. The text implies replicates were used (mitochondrial oxygen consumption assays were performed in the presence of 5 mM glutamate/2.5 mM malate for the analysis of Complex I-driven respiration...Data represent the average ± SEM of three independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Pink1-/- cells were rescued with human wild-type or with PINK1-containing clinical mutations. Human PINK1 (hPinklres) fully complemented Complex I enzymatic activity in Pink1¯/¯ mouse fibroblasts (Fig 5B and 6B). In contrast, two PD PINK1 clinical mutations W437X (Trp437 → Xxx)",
          "judgment": "Yes",
          "reasoning": "The study tested a known pathogenic variant (W437X) and used wild-type PINK1 as a control, fitting the criteria of using variant controls.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical analysis was done using the unpaired Student's t-test, where ***p = 0.00006, where **p < 0.004 and *p < 0.01 (Graph Pad Prism5 software).",
          "judgment": "No",
          "reasoning": "The study uses statistical tests (t-test) and provides p-values, but does not calculate or provide sufficient information to calculate OddsPath. ",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "NA",
          "judgment": "Yes",
          "reasoning": "Variant control testing was done using  PINK1 clinical mutations W437X. The study also rescued  PINK1−/− cells with wild-type human PINK1 (hPINK1res)",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "PINK1 W437X has supporting pathogenic functional evidence. Assays on Complex I function are considered to be applicable. Basic controls were used and there were known pathogenic variants used as controls. However, OddsPath could not be calculated and the number of pathogenic variants was fewer than 11."
    }
  ]
}
